Heterocyclic compounds constitute a central class of aromatic molecules in medicinal chemistry with benzimidazole derivatives emerging as one of the most significant and versatile scaffolds in modern drug design. First synthesized in the late nineteenth century, benzimidazole is a fused bicyclic system comprising a benzene ring and an imidazole ring and it is among the earliest nitrogen-containing heterocycles reported. Owing to its structural similarity to purine bases such as adenine and guanine, benzimidazole exhibits favourable physicochemical properties including tautomerism, that enable effective interactions with diverse biological targets such as enzymes and receptors. This structural advantage has positioned benzimidazole as a privileged pharmacophore in the development of bioactive molecules.

Extensive research over recent years has demonstrated that benzimidazole derivatives possess a wide spectrum of pharmacological activities, including anthelmintic, antibacterial, antifungal, antidepressant, anticancer, anticonvulsant, anti-inflammatory, antioxidant, antitubercular and antiviral effects. Numerous studies reported between 2022 and 2025 highlight the synthesis, characterization and biological evaluation of novel benzimidazole-based compounds, many of which exhibit comparable or superior activity to standard reference drugs across in vitro, in vivo and in silico models. Furthermore, several benzimidazole-containing drugs such as albendazole, mebendazole, omeprazole, telmisartan, candesartan and bendamustine are already established in clinical practice, underscoring the therapeutic importance of this scaffold.